You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Baxter
Medtronic
Dow
Harvard Business School

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REXULTI

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Rexulti

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03149991 A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD) Not yet recruiting Massachusetts General Hospital Phase 4 2017-06-01 This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable, and adequate antidepressant therapy (ADT) in the treatment of adults with Major Depressive Disorder with Treatment Resistant Depression.
NCT03418675 Brexpiprazole in Borderline Personality Disorder Not yet recruiting Otsuka America Pharmaceutical Phase 2 2018-07-01 The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be tested is that brexpiprazole will be more effective and well tolerated in adults with BPD compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder.
NCT03418675 Brexpiprazole in Borderline Personality Disorder Not yet recruiting University of Chicago Phase 2 2018-07-01 The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be tested is that brexpiprazole will be more effective and well tolerated in adults with BPD compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rexulti

Condition Name

Condition Name for Rexulti
Intervention Trials
Major Depressive Disorder 2
Borderline Personality Disorder 2
Post Traumatic Stress Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rexulti
Intervention Trials
Depressive Disorder 4
Depression 4
Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rexulti

Trials by Country

Trials by Country for Rexulti
Location Trials
United States 17
Canada 3
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rexulti
Location Trials
New York 3
Texas 3
California 2
Illinois 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rexulti

Clinical Trial Phase

Clinical Trial Phase for Rexulti
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rexulti
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 4
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rexulti

Sponsor Name

Sponsor Name for Rexulti
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 3
Otsuka America Pharmaceutical 2
University Health Network, Toronto 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rexulti
Sponsor Trials
Other 16
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Dow
McKesson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.